Hypertension and nephrology

[Cilostazol improves quality of life and lower limb functional capacity in lower extremity arterial disease regardless of age and gender – new results of the SHort-tERm cIlostazol eFFicacy and quality of life (SHERIFF) study]

FARKAS Katalin1,2, KOLOSSVÁRY Endre 1,2, JÁRAI Zoltán2,3

APRIL 22, 2022

Hypertension and nephrology - 2022;26(02)

DOI: https://doi.org/10.33668/hn.26.008

[Intermittent claudication has a significant negative impact on the patients’ quality of life. Revascularization procedures and noninvasive medical therapie scan improve walking capacity. Cilostazol has IA recommendation for the treatment of intermittent claudication (IC). The aim of this study was to evaluate the effect of three-month cilostazol treatment on the health related quality of life and on the lower limb functional capacity in women (F) and men (M), in patients under 65 years of age (Y) and among patients 65 years of age or older (O) with intermittent claudication in the clinical practice. The study was a multicenter, non-interventional trial, 812 lower extremity arterial disease (LEAD) patients (Fontaine II stage, mean age: 67.17 years, male/female: 58.25/41.75%, 506 patients aged ≥65 years) were enrolled, who received cilostazol (50 or 100 mg b.i.d.) for three months. Quality of life was evaluated with the EQ- 5D-3L questionnaire, functional capacity with the WELCH questionnaire. Walking distances, ankle-brachial index were measured at baseline and after 3-month. Upon conclusion of the study, the EQ-5D index improved (baseline: F [female] –0.49±0.23, M (male –0.44±0.22, Y (age <65 years) –0.45±0.21, O (age ≥65 years) –0.47±0.23; 3rd month: –0.27±0.18, –0.25±0.18, –0.25±0.18, –0.26±0.18; respectively, p<0.0001) and there was a significant increase in the WELCH score as well (baseline: F 18±13, M 20±14, Y 21±14, O 18±13; 3rd month: 31±18, 32±18, 32±19, 31±17; respectively, p<0.0001). Both pain-free and maximal walking distance increased: F 60.94%, (median: +50.26%), 49.57%, (median: + 42.86%), M 50.22%, (median: +50%), 37.7%, (median: + 33,33 %), Y 54,35 %, (median: + 56,2%), 36.78%, (median: +42.86%), O 54.62%, (median: +50%), 46.29% (median: +33.33%); respectively (p<0.001). Three months of cilostazol treatment improved quality of life and lower limb functional capacity in claudicant patients regardless of age and gender. The WELCH questionnaire is a useful tool in clinical practice for the evaluation of intermittent claudication treatment.]

AFFILIATIONS

  1. Dél-budai Centrumkórház Szent Imre Egyetemi Oktatókórház, Angiológia
  2. Semmelweis Egyetem, Angiológia Tanszéki Csoport
  3. Dél-budai Centrumkórház Szent Imre Egyetemi Oktatókórház, Kardiológia

COMMENTS

0 comments

Further articles in this publication

Hypertension and nephrology

[Chronic stress in the development of essential hypertension. Role of rilmenidine in the treatment of stress induced hypertension]

SIMONYI Gábor

[Hypertension is an independent risk factor of cardiovascular diseases. Several factors contribute to its development, including chronic stress, which may induce hypertension by increasing sympathetic activity. The signs of increasing sympathetic activity can be primarily detected in the initial phase of hypertension, which is characterized by the increase in cardiac output. In addition to the hemodynamic consequences (increase in cardiac output, tachycardia, coronary vasoconstriction, proarrhythmia), the increase in sympathetic activity has many harmful effects. Numerous metabolic (insulin resistance, dyslipidemia), structural and trophic effects (endothelial dysfunction, vascular hypertrophy, myocardial hypertrophy), as well as thrombotic and humoral processes (procoagulation, enhancement of thrombocyte aggregation, sodium retention, activation of the renin-angiotensin-aldosterone axis) may develop and consequently damage body functions at many targets. Several different antihypertensive drug classes are available for reducing increased sympathetic activity, including peripheral alpha and beta blockers and centrally acting drugs. First generation antihypertensive drugs with central mechanisms of action (e.g. clonidine, guanfacine, alpha-methyldopa) is currently rarely administered and only for a few indications as they have a significant adverse events profile. Among centrally acting, second generation drugs, rilmenidine stimulates imidazoline-I1 receptors and thus beneficially influences mild or moderate hypertension that involves enhanced sympathetic nervous system activity.]

Hypertension and nephrology

[Novelties in the diagnosis and treatment of X-linked hypophosphatemia]

RUESZ György Sándor, MIKES Bálint, CSIZEK Zsófia, HORVÁTH Orsolya

[X-linked hypophosphataemia (XLH) is the most common inherited cause of phosphate wasting. Its pathogenesis is complex, determined by the dysregulation of phosphate homeostasis and bone metabolism. We review herein the pathophysiology of XLH leading to multiple manifestations, stages of diagnosis and the treatment strategies. XLH is now in the scientific interest of pediatric nephrology, because a new treatment modality, burosumab became available in Hungary. Burosumab is a monoclonal antibody against fibroblast growth factor 23 (FGF-23). XLH is caused by the loss of function mutations in ”phosphate regulating endopeptidase homolog, X-linked” (PHEX) gene, which results enhanced secretion of the phosphaturic hormone FGF-23. The diagnosis of XLH is based on signs of rickets and/or osteomalacia and decreased growth velocity in association with hypophosphataemia and renal phosphate wasting in the absence of vitamin D or calcium deficiency. Conventional treatment with oral phosphate supplementation together with active vitamin D (calcitriol or alfadiol) can improve bone metabolism, but only partial results can be achieved, and can promote side effects (nephrocalcinosis). The better understanding of the role of PHEX gene and FGF-23 levels in the pathomechanism helped to identify therapeutic options more properly. With monoclonal antibody therapy against FGF-23 the disease process can be interrupted, and complications can be prevented if the therapy is initiated in time. However, deformities already leading to disability cannot regress completely during burosumab therapy, highlighting the need of early diagnosis and the start of the biological treatment before complications.]

Hypertension and nephrology

[Echocardiographic judgment of the left ventricular remodelling and heart failure’s types]

HATI Krisztina

[The heart responds to the damage to the heart muscle with various changes that are regulated by complex processes. If the harm is irreversible, changes that begin as an adaptation can become chronic and permanently worsen heart function. The author details below the pathological remodelling of the left ventricle that can lead to heart failure. It covers the types of heart failure based on the latest recommendations and presents the echocardiographic examination methods that can be used to assess the diastolic, systolic and right ventricular function of the heart.]

Hypertension and nephrology

[The importance of white-coat and masked hypertension: novelties]

ALFÖLDI Sándor

[White-coat hypertension is a heterogenous clinical entity includes patients with lower and higher cardiovascular risk. It has a relative benign prognosis if it is not associated with other cardiovascular risk factors. It can increase, however, significantly the risk of new onset sustained hypertension and diabetes. The risk of cardiovascular events is unequivocally higher than that of normotensive patients, according to recent studies. Therefore, the proper evaluation of cardiovascular risk has utmost importance in white-coat hypertensive patients to determine the adequate treatment and follow-up. Masked hypertension, in the other hand, is not a benign phenotype, therefore regular screening with out-of office blood pressure measurements and pharmacological blood pressure lowering therapy is mandatory.]

Hypertension and nephrology

[The efficiency of angiotensin receptor blocker/neprilysin inhibitor (ARNI) treatment in heart failure 2021 ARNI, VIDI, VICI…]

VÁRALLYAY Zoltán, KÉKES Ede

[A new compound ARNi (valsartan/sacubitril) – as a member of a new pharmacoterapeutic group – has several clinical evidences almost in the whole spectrum of heart failure, especially in case of reduced left ventricular ejection fraction and hypertension. The most important and essential evidence based studies and the efficiency of the treatment with ARNI in heart failure have been demonstrated in this overview. Due to the favorable results of the studies the recommendations of ARNI indication are increasingly dominant in the clinical guidelines. The usage provides effective, safe therapeutic help for the poor life expectancy heart failure patients in the everyday clinical practice. The treatment is already available in Hungary.]

All articles in the issue

Related contents

Journal of Nursing Theory and Practice

[Assessing Quality of life of Women with Cervical Cancer After Treatment]

KOZMANN Krisztina, JÁNOSNÉ PÁNKI Roxána, FERENCZY Mónika, KOMLÓSI Kálmánné, KARÁCSONY Ilona

[To assess sexual function, functionality and quality of life in women with cervical cancer. Descriptive, cross-sectional, quantitative, non-random, purposive sampling of women (N=91) with FIGO stage I/II/III cervical cancer, more than 5 months after last treatment. The study used standard questionnaires with self-designed questions. Data were analysed using Microsoft Excel, descriptive and mathematical statistics (p<0.05). Completers who received radiotherapy scored significantly higher in functional status (p<0.05) and emotional function than those who did not receive radiotherapy (p<0.05). Completers with lower levels of emotional well-being were significantly more likely to have lower levels of sexual function and higher levels of gynaecological problems (p<0.05). Women affected by cervical cancer often experience somatic and psychological disturbances that reflect on quality of life associated with the disease and treatment.]

Journal of Nursing Theory and Practice

[The Effect of Asthma Bronchiale on Everyday life Activities Among Adolescents]

RÁCZ Viktória Kinga, HEGEDŰS Bianka Ágnes , SZEBENI-KOVÁCS Gyula , FERENCZY Mónika

[The aim of this study is to assess the relationship between the physical activity of asthmatics, sleep disorders, the extent of asthma treatment, and to assess the quality of life in terms of physical activity. We conducted our quantitative, cross-sectional survey between 2020-2021. In a non-randomized, comfort sampling the target group was defined as adolescents aged between 14–18 years, their diagnosis of asthma bronchiale had to be for at least 1 year ago. The data were collected by a self-prepared questionnaire, the domains included: socio-demographic questions related to physical activites, symptoms, sleep disorders, severity of asthma. We used miniAQLQ to assess quality of life. The statistical analysis were performed by using Microsoft Excel 2016 and SPSS v 24 programs. Descriptive statistics (mean, standard deviation, minimum, maximum), two-sample t-test, Chi-square test were performed. The mean age of the respondents was 16±1.51, 38% were boys and 62% were girls (N=105). There was no significant difference between physical activity and the frequency of seizures and sleep disorders (p>0.05). There is a significant difference between the genders and the symptoms increasing with intense exercise (p=0.02). We found significant correlation between the active participations in physical education classes and the severity of the disease (p=0.021). There is a significant correlation between moderate-, social activities and physical activity (p<0.05). Appropriate health education, recommendation in career choices as well as in physical activities done by nurses may lead to decrease in the number of suffocation attacks in cases of adolescents suffering from asthma bronchiale.]

Clinical Neuroscience

[Disease burden of Duchenne muscular dystrophy patients and their caregivers]

PÉNTEK Márta, HERCZEGFALVI Ágnes, MOLNÁR Mária Judit, SZŐNYI László Pál, KOSZTOLÁNYI György, PFLIEGLER György, MELEGH Béla, BONCZ Imre, BRODSZKY Valentin, BAJI Petra, SZEGEDI Márta, POGÁNY Gábor, GULÁCSI László

[Background and purpose - Data on the disease burden of Duchenne Muscular Dystrophy are scarce in Hungary. The aim of this study was to assess patients’ and their caregivers’ health related quality of life and healthcare utilisations. Methods - A cross sectional survey was performed as part of the European BURQOL-RD project. The EQ-5D-5L and Barthel Index questionnaires were applied, health care utilisations and patients’ informal carers were surveyed. Results - One symptomatic female carer, 50 children (boys 94%) and six adult patients (five males) participated in the study, the latter two subgroups were included in the analysis. The average age was 9.7 (SD=4.6) and 24.3 (SD=9.8) years, respectively. Median age at time of diagnosis was three years. The average EQ-5D score among children and adults was 0.198 (SD=0.417) and 0.244 (SD=0.322), respectively, the Barthel Index was 57.6 (SD=29.9) and 53.0 (SD=36.5). Score of satisfaction with healthcare (10-point Likert-scale) was mean 5.3 (SD=2.1) and 5.3 (SD=2.9). 15 children were hospitalised in the past 12 months for mean 12.9 (SD=24.5) days. Two patients received help from professional carer. 25 children (mean age 11.1, SD=4.4 years) were helped/supervisied by principal informal carer (parent) for mean 90.1 (SD=44.4) hours/week and further family members helped in 21 cases. Correlation between EQ-5D and Barthel Index was strong and significant (0.731; p<0.01) as well as with informal care time (-0.770; p<0.01), but correlation with satisfaction with health care was not significant (EQ-5D: 0.241; Barthel Index: 0.219; informal care: -0.142). Conclusion - Duchenne muscular dystrophy leads to a significant deterioration in the quality of life of patients. Parents play outstanding role in the care of affected children. This study is the first in the Central and Eastern European region that provides quality of life data in this rare disease for further health economic studies.]

Clinical Neuroscience

[The quality of life of the cluster headache patients during the active phase of the headache]

DIÓSSY Mária, BALOGH Eszter, MAGYAR Máté, GYÜRE Tamás, CSÉPÁNY Éva, BOZSIK György, ERTSEY Csaba

[Introduction - Cluster headache (CH), which affects 0.1% of the population, is one of the most painful human conditions: despite adequate treatment, the frequent and severe headaches cause a significant burden to the patients. According to a small number of previous studies, CH has a serious negative effect on the sufferers’ quality of life (QOL). In the current study, we set out to examine the quality of life of the CH patients attending our outpatient service between 2013 and 2016, using generic and headache-specific QOL instruments. Methods - A total of 42 CH patients (16 females and 26 males; mean age: 39.1±13.5 years) completed the SF-36 generic QOL questionnaire and the headache- specific CHQQ questionnaire (Comprehensive Headache- related Quality of life Questionnaire), during the active phase of their headache. Their data were compared to those of patients suffering from chronic tension type headache (CTH) and to data obtained from controls not suffering from significant forms of headache, using Kruskal-Wallis tests. Results - During the active phase of the CH, the patients’ generic QOL was significantly worse than that of normal controls in four of the 8 domains of the SF-36 instrument. Apart from a significantly worse result in the ‘Bodily pain’ SF-36 domain, there were no significant differences between the CH patients’ and the CTH patients’ results. All the dimensions and the total score of the headache-specific CHQQ instrument showed significantly worse QOL in the CH group than in the CTH group or in the control group. Conclusion - Cluster headache has a significant negative effect on the quality of life. The decrease of QOL experienced by the patients was better reflected by the headache-specific CHQQ instrument than by the generic SF-36 instrument. ]

Clinical Neuroscience

[The changes in quality of life after instrumented surgical fusion of degenerative spondylolisthesis]

SÁRÓ Enikő, MISIK Ferenc, BANCZEROWSKI Péter

[Objective - There is no internationally accepted guideline for treatment of spondylolisthesis in the literature, otherwise this degenerative disease has great social and economical impact. There is no hungarian study examining the efficacy of instrumented fusion procedure in surgical treatment of spondylolisthesis. In current study we examined the effectiveness of fusion technique focusing on the impact of quality of life. Methods - Between 1st January, 2011 and 30th June, 2012 we examined a group of patients - who were operated on by instrumented fusion technique because of spondylolisthesis -, in the National Institute of Clinical Neurosciences, using the Oswestry Low Back Disability Questionnaire. All patients were treated after ineffective conservative treatment. The question was wheather how has changed the patients’ quality of life after the operation. Paired-sample t-test was used in this study. Results - Eighty-eight of the 97 examined patients reported different levels of impovement in the postoperative period, two patient’s condition has not changed in spite of the surgery, seven patient’s condition showed progression in average one year after the surgery. The pain improved most significantly (55.5%) (p<0.0001). Using the 16 point borderline according to the Questionnaire (over moderate disability), significant improvement was detected in 50 patients (51.5%). Succesful surgical result - according to the quality of life - was seen in 77.41% of male and in 50.98% of female patients. According to the different age groups, 72.72% of the younger (before retirement), and 53.06% of the retired patients belonged to this group. At least 15 point improvement was detected 35.05% of the patients, the overall improvement was 10.5 point. Discussion - Our results proved effectiveness of instrumented surgical fusion procedure in the treatment of degenerative spondylolisthesis. According to our results the younger male population with significant symptoms is the group, where improvement in quality of life is more pronaunced after the surgical procedure. Conclusion - The instrumented fusion surgical technique provides successful clinical and surgical outcome in patients with degenerative spondylolisthesis. It could improve the quality of life. Althought multicentre follow-up studies are needed to determine the exact indication and optimal therapy.]